Navigation Links
Accera, Inc. Announces Open-Label Data from Phase II Study in,Alzheimer's Disease at International Conference on Prevention of,Dementia

xtension rapidly showed significant improvement in memory and cognition, while AC-1202 appeared to have a disease stabilizing effect on subjects expressing the ApoE4 genotype (ApoE4(-)). Regardless of genotype, all subjects who remained on AC- 1202 for all nine months of the study showed very little disease progression, declining only 0.8 points below baseline in ADAS-Cog scores in contrast to the 5.4-point decline observed in placebo subjects extrapolated to nine months.

"The significant and rapid cognitive improvements observed in ApoE4(-) patients support the efficacy observed in our Phase IIa study," said Dr. Lauren Costantini, Accera's vice president of clinical development. "It also provides further evidence of the link between Alzheimer's disease and neuronal hypometabolism," she added, referring to AC-1202's novel mechanism of action.

AC-1202 continued to be well tolerated by subjects in the open-label extension study, providing an additional six months of safety data. The incidence of treatment-related gastrointestinal side effects was similar to that of other AD drugs in the double-blind phase of the study, but a reformulated version of AC-1202 used in the open-label extension study greatly reduced these side effects.

"The excellent safety profile of AC-1202 in addition to its efficacy on top of existing AD drugs makes it a strong candidate for a co-therapeutic approach to the treatment of Alzheimer's disease," said Dr. Steve Orndorff.

Open-label results were highlighted in a "Late Breaking News" press conference today at 1:30 p.m. (EDT) by the Alzheimer's Association. The 2nd Annual International Conference on Prevention of Dementia, a multidisciplinary forum for professionals from the fields of bench research, drug discovery, medicine, care and public policy, is hosted by the Alzheimer's Association, the leading voluntary health organization in Alzheimer care, support and research.

About AC-1202

Brain imaging tec
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Accera, Inc. Announces Results of Phase II Study in Alzheimers Disease at American Academy of Neurology Meeting
2. Accera, Inc. to Present Results of Phase II Study in Alzheimers Disease at American Academy of Neurology Meeting
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:8/1/2014)... N.J. , Aug. 1, 2014  PTC Therapeutics, ... on July 31, 2014 it approved non-statutory stock options ... common stock to seven new employees. The awards were ... a component of our new hires, employment compensation. ... Committee on July 31, 2014 and are being made ...
(Date:8/1/2014)... , Aug. 1, 2014  With monumental health reform ... speak a second language. Clinical efficacy is no longer ... under the ACA like PCORI are directing roughly $1 ... of new entities and environments, the federal healthcare ecosystem ... new language of outcomes and managed markets to the ...
(Date:8/1/2014)... YORK , Aug. 1, 2014  Valeant Pharmaceuticals ... L.P. today responded to the filing of a federal ... in California.  The complaint makes baseless claims about Valeant ... Allergan,s true purpose in bringing the litigation ... call a special meeting.  That purpose is made clear ...
Breaking Medicine Technology:PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 2Pharmaceuticals Learning the Language of the New Healthcare Landscape 2Pharmaceuticals Learning the Language of the New Healthcare Landscape 3Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 2Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 3Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 4Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 5Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 6
... 23, 2012  Doctors and other healthcare professionals have grown increasingly ... is taking with regard to Fosamax - a widely used ... fractures. The FDA has so far resisted ... prolonged use. Such labels are necessary in light of the ...
... BEIJING, Feb. 23, 2012 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical ... an emerging leader in the development, assembly, marketing and ... announced that for the year ended December 31, 2011, ... led by the Ministry of Science and Technology of ...
Cached Medicine Technology:Victims of Abnormal Bone Fractures Await Action as FDA Lingers on Edge of Tightening Fosamax Regulations 2Dehaier Medical Received Government Subsidy as a Certified High Technology Enterprise 2Dehaier Medical Received Government Subsidy as a Certified High Technology Enterprise 3
(Date:8/1/2014)... Cannabis use among young people has spiked, with ... used marijuana at least once and 17 percent admitting to ... Drugs, Say ‘Yes to Life,’ volunteers from the Church of ... with factual information about drugs, to help reverse this alarming ... to Drugs, Say ‘Yes’ to Life,” volunteers have distributed 40,000 ...
(Date:8/1/2014)... The Judicial Panel on Multidistrict Litigation ... therapy caused strokes, heart attacks, and other injuries in ... F. Kennelly as the transferee judge and ordered what ... federal court. , As one of his first organizing ... of attorneys who will move the litigation forward on ...
(Date:8/1/2014)... San Diego School of Medicine report that dietary capsaicin ... chronic activation of a receptor on cells lining the ... the risk of colorectal tumors. , The findings are ... The Journal of Clinical Investigation . , The receptor ... sensory neurons, where it acts as a sentinel for ...
(Date:8/1/2014)... at Washington University School of Medicine in St. Louis ... males and frequently are more harmful than similar tumors ... brain tumors, are diagnosed twice as often in males, ... not survive as long. , The researchers found that ... risk, is significantly less active in male brain cells ...
(Date:8/1/2014)... a central role in regulating appetite and whole-body metabolism. ... brain,s control of food intake and body weight, but ... been unclear. A new study in the ... activity in a type of neuron known as pro-opiomelanocortin ... high-fat diet. Sabrina Diano and colleagues at Yale ...
Breaking Medicine News(10 mins):Health News:Addressing a Serious Issue Affecting German Teens 2Health News:Judge Kennelly Appoints Attorney Michelle Kranz to the Plaintiffs’ Executive Committee in the Testosterone Replacement Therapy MDL 2Health News:Pepper and halt: Spicy chemical may inhibit gut tumors 2Health News:Study reveals one reason brain tumors are more common in men 2
... the University of Warwick and the Indian Institute of Technology ... to transport iron safely through our blood stream can, in ... fibrils banded by lines of iron rust. This process could ... the brain to cause some forms of Parkinsons & Alzheimers ...
... 8 Antidepressant medications,which increase serotonin neurotransmitter ... can increase depression, impulsivity and,suicide risk in ... physicians prescribe serotonin enhancement medications to dopamine,deficient ... and,suicidal," said Dr. Rick Sponaugle, Medical Director ...
... tool powered by SNAPforSeniors(R) helps members quickly,locate safe housing, ... rash of tornadoes in more than 20 years destroyed ... Tennessee Tuesday night., Emergency warnings gave most residents ... housing, natural disasters bring extra fears. Lack,of mobility, limited ...
... NightHawk,Radiology Holdings, Inc. (Nasdaq: NHWK ), a ... United States, announced today that,the time of its fourth ... to February 13, 2008 at 4:30 p.m. (ET). The ... on February 13, 2008., Conference Call & Web ...
... (Nasdaq: MLAB ) today announced that its ... dividend of ten cents per share of common,stock, ... record at the close of,business on February 25, ... markets,electronic instruments for industrial, pharmaceutical and medical,applications., ...
... poorly one year later, study found , , FRIDAY, Feb. 8 ... sufficient reason for most people to change to a heart-healthy ... quality is poor after a coronary heart disease event," said ... at the University of Massachusetts Medical School, in Worcester. , ...
Cached Medicine News:Health News:Iron banded worms drying out of blood could be linked to Parkinson's and Alzheimer's 2Health News:Antidepressants Can Increase Depression, Impulsivity and Suicide Risk by Decreasing Dopamine 2Health News:Antidepressants Can Increase Depression, Impulsivity and Suicide Risk by Decreasing Dopamine 3Health News:Tennessee Tornadoes Spur Senior Move Managers to Aid Elderly in Crisis 2Health News:Tennessee Tornadoes Spur Senior Move Managers to Aid Elderly in Crisis 3Health News:NightHawk Radiology Holdings, Inc. Announces Time Change for Fourth Quarter and Full-Year 2007 Earnings Conference Call 2Health News:Heart Attack Seldom Leads to Healthier Diet 2Health News:Heart Attack Seldom Leads to Healthier Diet 3
... is powerful, lightweight, easy ... soft, durable foam silicone ... covered by machine washable ... headband easily adjusts to ...
... is powerful, lightweight, easy ... soft, durable foam silicone ... covered by machine washable ... headband easily adjusts to ...
Solarc surgical headlight is durable, comfortable, lightweight and delivers the bright, white light expected from a xenon system, but at a fraction of the cost....
View Mex-3 is designed for out-patient surgery, hospital rounds and house calls....
Medicine Products: